Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...

Phase III data for dapirolizumab pegol presented at the 2025 conference of the American College of Rheumatology showed ...

The recent passing of singer Selena has shocked fans and friends alike, highlighting the serious impact of lupus, a chronic autoimmune disease. This article explores the implications of lupus, the ...

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus ...

Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease ...

CHICAGO -- People who died with systemic lupus erythematosus (SLE) were far more likely than car crash victims to have severe ...

Deucravacitinib reduces circulating proteins associated with kidney dysfunction in patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2025.“Specific plasma ...

The Lupus Foundation of America (LFA) proudly presented eight abstracts and sessions during the 2025 American College of Rheumatology (ACR) Convergence with the goal of advancing science, improving ...

Recognizing the early signs of lupus is crucial for timely intervention. The following are some common symptoms associated with the disease: Fatigue and malaise: Many patients report a persistent ...

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research ...

Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...